The treatment of pancreatic cancer.
Yeo
C J
CJ
Department of Surgery, Johns Hopkins Medical Institutions, Baltimore, MD 21287-4606, USA. cyeo@jhmi.edu
Cameron
J L
JL
D000230:Adenocarcinoma / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001706:Biopsy; D021441:Carcinoma, Pancreatic Ductal / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002760:Cholangiopancreatography, Endoscopic Retrograde; D002986:Clinical Trials as Topic; D005472:Fluorouracil / Q000627:therapeutic use; D015316:Genetic Therapy; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008197:Lymph Node Excision; D008279:Magnetic Resonance Imaging; D010166:Palliative Care; D010179:Pancreas / Q000473:pathology; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D016577:Pancreaticoduodenectomy; D011184:Postoperative Period; D011446:Prospective Studies; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D013997:Time Factors; D014057:Tomography, X-Ray Computed
D000964:Antimetabolites, Antineoplastic; D002955:Leucovorin; D005472:Fluorouracil